Jaguar Health, Inc. (JAGX): Shareholders' Equity
-$18.69M
As of 2025-12-31
$4.92M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$18.69M | n/m | 2026-04-07, Balance as of period end |
| 2024-12-31 | $6.49M | +32.6% | 2026-04-07, Balance as of period end |
| 2023-12-31 | $4.90M | n/m | 2025-03-31, Balance as of period end |
| 2022-12-31 | -$1.36M | n/m | 2024-04-01, Balance as of period end |
| 2021-12-31 | $11.85M | -31.1% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $17.20M | +61.2% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $10.67M | +98.3% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $5.38M | -68.8% | 2020-04-03, Balance as of period end |
| 2017-12-31 | $17.26M | n/m | 2019-04-10, Balance as of period end |
| 2016-12-31 | -$2.45M | n/m | 2018-04-09, Balance as of period end |
| 2015-12-31 | $4.40M | n/m | 2017-02-15, Balance as of period end |
| 2014-12-31 | -$8.24M | n/a | 2016-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$18.69M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $68.64M | -47.8% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $203.01M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$63.61M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | $205.57M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $245.15M | +75.7% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $956.82M | -6.4% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $242.14M | -22.5% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $20.91M | -45.7% |
Compare JAGX, PRLD, CBIO, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗